Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen.
about
In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccinationAntigen-specific immunotherapy of cervical and ovarian cancerA combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effectsSynergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells.Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potencyDNA vaccines for cervical cancerActivation of Akt as a mechanism for tumor immune evasion.Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity.Therapeutic HPV DNA vaccines.Perspectives for preventive and therapeutic HPV vaccines.Immunotherapy for cervical cancer: Research status and clinical potentialVaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein DEfficient delivery of DNA vaccines using human papillomavirus pseudovirionsImproving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigenOvarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk geneOptimization of a self antigen for presentation of multiple epitopes in cancer immunityXenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.Bugs as drugs for cancer.Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins.DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cellsDNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunityVaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell lifeDNA vaccines for cervical cancer: from bench to bedside.Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell.Mechanisms of immunization against cancer using chimeric antigens.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Developing a Novel Gene-Delivery Vector System Using the Recombinant Fusion Protein of Pseudomonas Exotoxin A and Hyperthermophilic Archaeal Histone HPhA.Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protectionTumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen.Generation and characterization of a preventive and therapeutic HPV DNA vaccinePreventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical CancersEnhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.Trial watch: DNA vaccines for cancer therapy.DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies.Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.Development of a DNA vaccine targeting Merkel cell polyomavirusAdministration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.
P2860
Q21195875-6CF5D834-3B60-48B2-9808-EC0F89E22A7FQ27488697-FD37F867-C175-4497-AB0F-2A20F613F8E1Q30443978-7AD4EE39-EFBE-406B-8FB6-4F736F18F4AFQ33581597-E271F008-4BB4-43CA-AEE7-012E24C149ECQ33589738-017F822F-4550-4C82-99A3-6C153326E73DQ33649019-05D5D14E-0489-4853-83D9-18E1EB634064Q33680693-B133296D-89EB-4272-81D5-E21D93515418Q33713327-1DB0E76D-E755-4041-9009-7E9BA8D97D52Q33817957-4C629A3D-A7BE-4E7B-8AD7-E6DD499349A6Q33936427-57A963B2-5069-4F0B-B389-F120C7ED3324Q34011494-6515D7ED-BB71-4037-8F82-06E44245A31DQ34033763-A386EA8D-F8BD-482C-B41D-C720AD92668CQ34078674-1173C8AD-9531-4AF7-8664-922ED5DB377AQ34189966-0C96F97E-5759-4C79-B48F-2F2CB2C6D634Q34274080-63235650-9B43-4CF1-990F-9AAA19C67000Q34332858-0E55B4FE-3173-47F7-8A78-3D3F61CDB647Q34345491-B320D0E1-4D65-46E4-AA15-F875035B9F22Q34537491-8AF8E944-F63D-4B5F-B20E-FC06B1F8A6AFQ34607207-D49C5EDE-400E-4576-85E7-4088A1BF27F6Q34842154-108C9C4E-6ABE-4A0A-BF81-688C11C1069BQ35108258-D1CDEFB2-3E80-4F1B-9249-25A2B6C6768EQ35148074-17FB0527-F194-4483-B622-C36DBCF921FDQ35184078-DF2DF594-67A8-48FB-AE63-C64EEA43A3E0Q35234876-2356A430-4ACD-4706-960A-ED97E4BD18F6Q35234992-B17A0445-1BD3-4BDE-83BD-101D3E2C4A09Q35401109-7AF79BA4-8AC1-423A-88BA-C049AED345B5Q35442846-FBE7DBD8-D71C-4D0F-8F85-1D566F372D87Q35527165-9C8537F6-77C0-439C-A437-DF048EE1278BQ35837728-18CE0CB3-836E-44D9-A6BD-7461924F398DQ36095558-6185BDD0-95B4-4168-B056-1F26B67378DCQ36167792-9C6FC16E-3942-4E0E-8965-3F2A543C51A8Q36402453-B9E7731C-E3CA-4CA5-93B3-2EC61CA2523EQ36482161-50735D66-0B65-4068-A2B5-A635EC0E7C71Q36652548-F19621EB-B557-4E14-AD4E-96E2B289E5BBQ36780146-1FB9DE9B-BC27-440B-9BE3-CF63FDE2B8B8Q36845824-550C6BF0-27B4-42AC-A3C7-2271998A41CDQ37010987-925CA6F8-0E2B-4F1D-9539-840092769D2BQ37198835-CAA1FA2A-9DC8-4194-A103-24E83DD76B58Q37200390-49A52C36-B708-409E-8C99-80C99BD4B7B2Q37351412-6DF18A20-A70B-48BE-AD3C-CC9AA058BCEB
P2860
Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Cancer immunotherapy using a D ...... xin linked to a tumor antigen.
@en
Cancer immunotherapy using a D ...... xin linked to a tumor antigen.
@nl
type
label
Cancer immunotherapy using a D ...... xin linked to a tumor antigen.
@en
Cancer immunotherapy using a D ...... xin linked to a tumor antigen.
@nl
prefLabel
Cancer immunotherapy using a D ...... xin linked to a tumor antigen.
@en
Cancer immunotherapy using a D ...... xin linked to a tumor antigen.
@nl
P2093
P1433
P1476
Cancer immunotherapy using a D ...... oxin linked to a tumor antigen
@en
P2093
P304
P407
P577
2001-05-01T00:00:00Z